{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:10Z","timestamp":1791644770702,"version":"4.3.4"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Dry eye disease (DED) is a common chronic ocular disease. DED can have a significant impact on visual function, causing disturbances to comfort, daily activities, and general quality of life. The varied nature of DED makes it difficult to point to a specific cause of the syndrome. However, current literature agrees that the inflammation of the cornea and conjunctiva plays a major role in its pathogenesis. Therapies targeted toward inflammation have shown varied success in the treatment of DED. The purpose of this review is to provide an overview of the prevalence and inflammatory pathophysiology of DED and discussion of the available anti-inflammatory therapies including the following: Nonsteroidal anti-inflammatory drugs, corticosteroids, and other hormonal therapies, nonsteroidal immunomodulators, biological tear replacement, antibiotics, dietary supplements, tea tree oil, and intense pulsed light.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2211-5056.369606","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T02:02:02Z","timestamp":1676253722000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Dry eye disease"],"prefix":"10.4103","volume":"13","author":[{"given":"Annie","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kolluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Beglarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240830","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-2-20240830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","article-title":"Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older","volume":"182","author":"Farrand","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R3-2-20240830","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1167\/iovs.17-23651","article-title":"Inflammatory response in dry eye","volume":"59","author":"Yamaguchi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-2-20240830","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/NHH.0000000000000652","article-title":"Dry eye disease: Prevalence, assessment, and management","volume":"36","author":"Rouen","year":"2018","journal-title":"Home Healthc Now"},{"key":"R5-2-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1874364101711010355","article-title":"Determination of risk factors and treatment of dry eye disease in type 1 diabetes before corneal complications at Sindh institute of ophthalmology and visual sciences","volume":"11","author":"Shujaat","year":"2017","journal-title":"Open Ophthalmol J"},{"key":"R6-2-20240830","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4103\/ijo.IJO_3250_20","article-title":"Mask-associated dry eye disease and dry eye due to prolonged screen time: Are we heading towards a new dry eye epidemic during the COVID-19 era?","volume":"69","author":"Pandey","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R7-2-20240830","first-page":"240","article-title":"Dry eye: An inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"R8-2-20240830","doi-asserted-by":"crossref","first-page":"771352","DOI":"10.3389\/fmed.2021.771352","article-title":"Estimated annual economic burden of dry eye disease based on a multi-center analysis in China: A retrospective study","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med (Lausanne"},{"key":"R9-2-20240830","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"R10-2-20240830","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICL.0000000000000042","article-title":"The core mechanism of dry eye disease is inflammation","volume":"40","author":"Wei","year":"2014","journal-title":"Eye Contact Lens"},{"key":"R11-2-20240830","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10792-014-9969-x","article-title":"The role and treatment of inflammation in dry eye disease","volume":"34","author":"Yagci","year":"2014","journal-title":"Int Ophthalmol"},{"key":"R12-2-20240830","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R13-2-20240830","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1167\/iovs.07-0069","article-title":"Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma","volume":"48","author":"De Paiva","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-2-20240830","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaut.2008.04.017","article-title":"Role of Th1 and Th17 cells in organ-specific autoimmunity","volume":"31","author":"Dardalhon","year":"2008","journal-title":"J Autoimmun"},{"key":"R15-2-20240830","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2016.0105","article-title":"LFA-1\/ICAM-1 interaction as a therapeutic target in dry eye disease","volume":"33","author":"Pflugfelder","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"R16-2-20240830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R17-2-20240830","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","article-title":"Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis","volume":"19","author":"Avisar","year":"2000","journal-title":"Cornea"},{"key":"R18-2-20240830","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/ICO.0000000000000309","article-title":"Topical NSAIDs effect on corneal sensitivity","volume":"34","author":"Singer","year":"2015","journal-title":"Cornea"},{"key":"R19-2-20240830","first-page":"205","article-title":"Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs","volume":"99","author":"Flach","year":"2001","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R20-2-20240830","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcrs.2016.06.006","article-title":"Cataract surgery and nonsteroidal antiinflammatory drugs","volume":"42","author":"Hoffman","year":"2016","journal-title":"J Cataract Refract Surg"},{"key":"R21-2-20240830","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/OPTH.S23381","article-title":"Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction","volume":"6","author":"Carre\u00f1o","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R22-2-20240830","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: A randomized controlled clinical trial","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"key":"R23-2-20240830","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2015.04.008","article-title":"Effects of dry eye therapies on environmentally induced ocular surface disease","volume":"160","author":"Moore","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R24-2-20240830","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12325-016-0315-8","article-title":"Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure","volume":"33","author":"Sheppard","year":"2016","journal-title":"Adv Ther"},{"key":"R25-2-20240830","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R26-2-20240830","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"R27-2-20240830","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The Cyclosporin A Phase 2 study group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R28-2-20240830","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 study group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"R29-2-20240830","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.sjopt.2018.06.001","article-title":"Efficacy and safety of using topical cyclosporine a for treatment of moderate to severe dry eye disease","volume":"32","author":"Othman","year":"2018","journal-title":"Saudi J Ophthalmol"},{"key":"R30-2-20240830","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40662-017-0072-z","article-title":"Topical tacrolimus in anterior segment inflammatory disorders","volume":"4","author":"Shoughy","year":"2017","journal-title":"Eye Vis (Lond"},{"key":"R31-2-20240830","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/ICO.0b013e31823f8c9b","article-title":"Clinical treatment of dry eye using 0.03% tacrolimus eye drops","volume":"31","author":"Moscovici","year":"2012","journal-title":"Cornea"},{"key":"R32-2-20240830","first-page":"C05","article-title":"Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases","volume":"10","author":"Barot","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R33-2-20240830","doi-asserted-by":"crossref","first-page":"2515841419870366","DOI":"10.1177\/2515841419870366","article-title":"Lifitegrast: A novel drug for patients with dry eye disease","volume":"11","author":"Haber","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"key":"R34-2-20240830","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","article-title":"Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: A Post hoc analysis of 2 randomized clinical trials","volume":"139","author":"Holland","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R35-2-20240830","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: Results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"R36-2-20240830","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajo.2008.08.032","article-title":"Tear cytokine profiles in dysfunctional tear syndrome","volume":"147","author":"Lam","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R37-2-20240830","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: A randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R38-2-20240830","first-page":"4874","article-title":"Effect of androgen deficiency on the human meibomian gland and ocular surface","volume":"85","author":"Krenzer","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-2-20240830","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajo.2018.09.021","article-title":"A randomized controlled double-masked study of transdermal androgen in dry eye patients associated with androgen deficiency","volume":"197","author":"Supalaset","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R40-2-20240830","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1167\/iovs.05-1003","article-title":"Estrogen's and progesterone's impact on gene expression in the mouse lacrimal gland","volume":"47","author":"Suzuki","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-2-20240830","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/01.GME.0000063568.84134.35","article-title":"Effects of hormone replacement therapy on ocular function in postmenopause","volume":"10","author":"Affinito","year":"2003","journal-title":"Menopause"},{"key":"R42-2-20240830","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5122(02)00316-X","article-title":"Tear function changes of postmenopausal women in response to hormone replacement therapy","volume":"44","author":"Kuscu","year":"2003","journal-title":"Maturitas"},{"key":"R43-2-20240830","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.maturitas.2006.08.007","article-title":"Dry eye in post-menopausal women using hormone replacement therapy","volume":"56","author":"Erdem","year":"2007","journal-title":"Maturitas"},{"key":"R44-2-20240830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/bjo.39.2.90","article-title":"Kerato-conjunctivitis sicca treated with cortisone and ACTH","volume":"39","author":"Eadie","year":"1955","journal-title":"Br J Ophthalmol"},{"key":"R45-2-20240830","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40123-022-00501-2","article-title":"Results from a prospective, open-label, phase 4 pilot study of repository Corticotropin injection for moderate and severe dry eye disease","volume":"11","author":"Toyos","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R46-2-20240830","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1093\/rheumatology\/keaa076","article-title":"Follow-up results of myositis patients treated with H. P. Acthar gel","volume":"59","author":"Saygin","year":"2020","journal-title":"Rheumatology (Oxford"},{"key":"R47-2-20240830","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","article-title":"The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction","volume":"19","author":"Yoo","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"R48-2-20240830","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/bjo.2006.091579","article-title":"Short term oral minocycline treatment of meibomianitis","volume":"90","author":"Aronowicz","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R49-2-20240830","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/ICL.0000000000000729","article-title":"Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis","volume":"47","author":"Arita","year":"2021","journal-title":"Eye Contact Lens"},{"key":"R50-2-20240830","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jtos.2019.07.003","article-title":"Patient-reported outcomes of autologous serum tears for the treatment of dry eye disease in a large cohort","volume":"17","author":"Kreimei","year":"2019","journal-title":"Ocul Surf"},{"key":"R51-2-20240830","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1705566","article-title":"Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease","volume":"39","author":"Yoon","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R52-2-20240830","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R53-2-20240830","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/ICO.0000000000002943","article-title":"Short-term efficacy and safety of biological tear substitutes and topical secretagogues for dry eye disease: A systematic review and network meta-analysis","volume":"41","author":"Jongkhajornpong","year":"2022","journal-title":"Cornea"},{"key":"R54-2-20240830","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","article-title":"Amniotic membrane extract eye drops: A new approach to severe ocular surface pathologies","volume":"23","author":"P\u00e9rez","year":"2022","journal-title":"Cell Tissue Bank"},{"key":"R55-2-20240830","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/OPTH.S162203","article-title":"Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study","volume":"12","author":"McDonald","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R57-2-20240830","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s10792-021-01856-4","article-title":"Amniotic membrane extract eye drops for ocular surface diseases: Use and clinical outcome in real-world practice","volume":"41","author":"Sabater-Cruz","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R58-2-20240830","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2478\/sjecr-2019-0072","article-title":"Therapeutic potential of \u201cderived-multiple allogeneic proteins paracrine signaling-d-mapps\u201d in the treatment of dry eye disease","volume":"23","author":"Harrell","year":"2022","journal-title":"Serbian J Exp Clin Res"},{"key":"R59-2-20240830","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11745-001-0812-7","article-title":"Polyunsaturated fatty acids, inflammation, and immunity","volume":"36","author":"Calder","year":"2001","journal-title":"Lipids"},{"key":"R60-2-20240830","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/ICO.0000000000000940","article-title":"Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes","volume":"35","author":"Epitropoulos","year":"2016","journal-title":"Cornea"},{"key":"R61-2-20240830","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2147\/OPTH.S62470","article-title":"Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction","volume":"8","author":"Ole\u00f1ik","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R62-2-20240830","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"n-3 fatty acid supplementation for the treatment of dry eye disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N Engl J Med"},{"key":"R63-2-20240830","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/eye.2010.7","article-title":"Tear proteomics in evaporative dry eye disease","volume":"24","author":"Versura","year":"2010","journal-title":"Eye (Lond"},{"key":"R64-2-20240830","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1755-3768.1994.tb02791.x","article-title":"Ocular surface damage and tear lactoferrin in dry eye syndrome","volume":"72","author":"Danjo","year":"1994","journal-title":"Acta Ophthalmol (Copenh"},{"key":"R65-2-20240830","doi-asserted-by":"crossref","first-page":"389S","DOI":"10.1080\/07315724.2001.10719173","article-title":"Antiinflammatory activities of lactoferrin","volume":"20","author":"Conneely","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"R66-2-20240830","first-page":"C06","article-title":"Effect of oral lactoferrin on cataract surgery induced dry eye: A randomised controlled trial","volume":"9","author":"Devendra","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"R67-2-20240830","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ophtha.2007.06.027","article-title":"Lactoferrin in Sj\u00f6gren's syndrome","volume":"114","author":"Dogru","year":"2007","journal-title":"Ophthalmology"},{"key":"R68-2-20240830","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.2.7.2","article-title":"Terpinen-4-ol is the most active ingredient of tea tree oil to kill Demodex mites","volume":"2","author":"Tighe","year":"2013","journal-title":"Transl Vis Sci Technol"},{"key":"R69-2-20240830","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3346\/jkms.2012.27.12.1574","article-title":"Ocular surface discomfort and Demodex: Effect of tea tree oil eyelid scrub in Demodex blepharitis","volume":"27","author":"Koo","year":"2012","journal-title":"J Korean Med Sci"},{"key":"R70-2-20240830","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archderm.1963.01590210056008","article-title":"Demodex Folliculorum and blepharitis","volume":"88","author":"Post","year":"1963","journal-title":"Arch Dermatol"},{"key":"R71-2-20240830","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/bjo.2005.072363","article-title":"In vitro and in vivo killing of ocular Demodex by tea tree oil","volume":"89","author":"Gao","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R72-2-20240830","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ICU.0000000000000168","article-title":"Recent advances on ocular Demodex infestation","volume":"26","author":"Cheng","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"R73-2-20240830","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2133.2008.08702.x","article-title":"Treatment of rosacea with intense pulsed light: Significant improvement and long-lasting results","volume":"159","author":"Papageorgiou","year":"2008","journal-title":"Br J Dermatol"},{"key":"R74-2-20240830","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/pho.2014.3819","article-title":"Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study","volume":"33","author":"Toyos","year":"2015","journal-title":"Photomed Laser Surg"},{"key":"R75-2-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/OPTO.S217639","article-title":"Intense pulsed light therapy in the treatment of meibomian gland dysfunction: Current perspectives","volume":"11","author":"Giannaccare","year":"2019","journal-title":"Clin Optom (Auckl"},{"key":"R76-2-20240830","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajo.2017.08.021","article-title":"Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction","volume":"183","author":"Liu","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R77-2-20240830","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1167\/iovs.14-15764","article-title":"Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction","volume":"56","author":"Craig","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R78-2-20240830","first-page":"178","article-title":"Safety and efficacy of an augmented intense pulse light protocol for dry eye syndrome and blepharitis","volume":"39","author":"Zhang-Nunes","year":"2021","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"R79-2-20240830","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/ICO.0000000000002954","article-title":"Clinical and molecular outcomes after combined intense pulsed light therapy with low-level light therapy in recalcitrant evaporative dry eye disease with meibomian gland dysfunction","volume":"41","author":"D'Souza","year":"2022","journal-title":"Cornea"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.369606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:19:01Z","timestamp":1787836741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.369606"}},"subtitle":["A review of anti-inflammatory therapies"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/2211-5056.369606","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}